PAVmed Inc. (PAVM) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
PAVmed Inc. (PAVM) dropped -5.29% to $1.97, trading at 2% of its 52-week range ($1.84 – $28.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will ho
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a busine
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA) stock rose
RingCentral surged 15% after beating Q3 estimates and raising FY26 guidance; XXII, LABT and HUBC led premarket gainers, while LNAI fell.
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has begun receivin
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics (NASDAQ:AARD) stock
On September 22, Lucid announced that it would begin submitting Medicare claims for EsoGuard tests performed at one of its two CLIA-certified laboratories. Shortly thereafter, the Company began receiving payments on
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PAVM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PAVM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, PAVmed Inc. (PAVM) ranks #935 by composite RQD confidence (31/100, grade E) and #856 by equity capitalization ($15.8M). Within this direct 5-issuer industry benchmark cohort, PAVM leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. MODD currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with PAVM at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PAVM
ACTIVE
PAVmed Inc. | E | 31/100 | — | -30.0% | -35.0% | -5.29% | $15.8M | Benchmark Subject |
| MODD Modular Medical Inc. | D- | 36/100 | — | — | -35.0% | -9.95% | $16.3M | /modd-vs-pavm → |
| RVP Retractable Technologies Inc. | E | 33/100 | — | 0.1% | -23.3% | -1.15% | $17.3M | /rvp-vs-pavm → |
| CTSO Cytosorbents Corporation | E | 21/100 | — | 71.5% | -35.0% | -16.03% | $13.9M | /ctso-vs-pavm → |
| CNSY Cerenome Inc. | D- | 36/100 | — | — | -35.0% | 0.00% | $13.2M | /cnsy-vs-pavm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), PAVmed Inc. (PAVM) reported GAAP revenue of $71.0K (-97.6% vs. FY2024 revenue of $3.0M , and -97.1% cumulative change since FY2023) , GAAP net income of -$3.8M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+84.4% YoY). On the balance sheet, PAVM closed FY2025 with $38.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $71.0K | -$3.8M | -$5.2M | -$5.2M | $38.8M | — |
| FY2024 (FY) | 2024-12-31 | $3.0M | $32.0M | -$33.6M | -$33.6M | $30.7M | — |
| FY2023 (FY) | 2023-12-31 | $2.5M | -$66.3M | -$52.0M | -$52.0M | — | — |
As of 2026-11-01, PAVmed Inc. (NASDAQ: PAVM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.97 (-5.29% 1D, market cap $15.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PAVM ranks #935 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), PAVM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MODD (Modular Medical Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and RVP (Retractable Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -23.3%, cap $17.3M). Among the 5-stock peer group, PAVM leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).
Per PAVM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001624326), PAVmed Inc. generated $71.0K in revenue (-97.6% YoY), -$3.8M in net income, and -$5.2M in free cash flow against $38.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PAVM last traded at $1.97 (-5.29% on volume of 5,357 shares), positioning the stock -44.82% below its 50-day simple moving average ($3.57) and -70.02% below its 200-day simple moving average ($6.57). Across its 52-week range of $1.84 to $28.44, PAVM sits at the 0.5% percentile with a 14-day RSI of 26.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.72 to $2.22).
Why PAVM Stock dropped -5.29% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.